Last reviewed 2026-05-27 · How we verify

Thiuram (THIRAM)

Phase 2 active Small molecule ✓ Verified May 2026

Thiuram (generic name: THIRAM) is a drug. It is currently in Phase 2 development.

Thiuram is a small molecule with the following synonyms: NSC-1771, NSC-49512, NSC-59637, NSC-622696, REZIFILM, and SQ 1489.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	THIRAM
Target	Lysyl oxidase homolog 2, Lysyl oxidase homolog 3, Lysyl oxidase homolog 4
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Thiuram CI brief — competitive landscape report
Thiuram updates RSS · CI watch RSS

Frequently asked questions about Thiuram

What is Thiuram?

Thiuram (THIRAM) is a Small molecule drug.

What is the generic name of Thiuram?

THIRAM is the generic (nonproprietary) name of Thiuram.

What development phase is Thiuram in?

Thiuram is in Phase 2.

What does Thiuram target?

Thiuram targets Lysyl oxidase homolog 2, Lysyl oxidase homolog 3, Lysyl oxidase homolog 4.

Target: All drugs targeting Lysyl oxidase homolog 2, Lysyl oxidase homolog 3, Lysyl oxidase homolog 4
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing